Clinical Trial Update: A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate [Phase 3]

View source ↗

Summary

A two-year Phase 3 study of CP-690,550 (tofacitinib) in rheumatoid arthritis patients on background methotrexate completed; results were posted in January 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2013-01-09